Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5511683 | 0.92 | P2RY12 (0.48) | P2RY12ALDH1A1SMN1; SMN2FBP1F10 | |
| SCHEMBL5512246 | 0.91 | P2RY12 (0.38) | P2RY12F10 | |
| SCHEMBL5547100 | 0.88 | P2RY12 (0.48) | P2RY12F10 | |
| SCHEMBL14522015 | 0.86 | P2RY12 (0.33) | P2RY12ALDH1A1SMN1; SMN2FBP1 | |
| SCHEMBL14522018 | 0.84 | P2RY12 (0.41) | P2RY12ALDH1A1SMN1; SMN2FBP1 | |
| SCHEMBL14544550 | 0.83 | P2RY12 (0.32) | P2RY12ALDH1A1SMN1; SMN2F10 | |
| SCHEMBL14522019 | 0.83 | P2RY12 (0.46) | P2RY12FBP1F10 | |
| SCHEMBL14522009 | 0.83 | P2RY12 (0.47) | P2RY12FBP1F10 | |
| SCHEMBL5513366 | 0.82 | P2RY12 (0.47) | P2RY12ALDH1A1SMN1; SMN2FBP1F10 | |
| SCHEMBL14522023 | 0.80 | P2RY12 (0.46) | P2RY12SMN1; SMN2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | TBXAS1, TBXA2R, SERPINC1 | P2RY12 677/4885ALDH1A1 704/4885SMN1; SMN2 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.